 |
10 Diseases |  |
4 Trials |
|
4 Trials |  |
37 News |  |
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial completion date, Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 15, 2024
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Trial completion date: Sep 2029 --> Oct 2031 | Trial primary completion date: Jul 2024 --> Oct 2026
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, NN1213 / Novo Nordisk
Trial completion date, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Apr 4, 2024
P2, N=110, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Jan 2, 2024
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2029 --> Oct 2031 | Trial primary completion date: Jul 2024 --> Oct 2026 Trial completion date: Dec 2023 --> Dec 2024
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - May 23, 2023
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jun 2023 --> Dec 2023
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Apr 19, 2023
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Dec 2023 Trial completion date: Dec 2022 --> Jun 2023
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial completion date, Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - May 31, 2022
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Trial completion date: Dec 2022 --> Jun 2023 Trial completion date: Sep 2022 --> Sep 2029 | Trial primary completion date: Jul 2022 --> Jul 2024
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Dec 17, 2021
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2022 --> Sep 2029 | Trial primary completion date: Jul 2022 --> Jul 2024 Trial completion date: Dec 2021 --> Dec 2022
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment closed: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Nov 23, 2021
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Dec 2022 Recruiting --> Active, not recruiting
- tadalafil / Generic mfg.
[VIRTUAL] THE REVERSAL OF IMMUNE EXCLUSION MEDIATED BY TADALAFIL AND AN ANTI-TUMOR VACCINE ALSO INDUCES PDL1 UP REGULATION IN RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA: FINAL ANALYSIS INCLUDING CLINICAL OUTCOMES OF A PHASE I CLINICAL TRIAL () - Aug 3, 2021 - Abstract #AHNS2021AHNS_649;
P1/2
All patients were previously irradiated as per study protocol, with 5 of 7 on the active treatment arm and 5 of 6 on the control arm receiving chemotherapy with radiation therapy as part of their prior treatment. Long term (two years) clinical outcomes and toxicity data of 7 evaluable treatment patients and 6 control patients will be reported in addition to long term analyses of the immunomodulatory effects of the treatment intervention.
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date, Trial primary completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Dec 17, 2020
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Long term (two years) clinical outcomes and toxicity data of 7 evaluable treatment patients and 6 control patients will be reported in addition to long term analyses of the immunomodulatory effects of the treatment intervention. Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment open: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - May 21, 2020
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021 Suspended --> Recruiting
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial completion date, Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 6, 2020
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Suspended --> Recruiting Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial suspension: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Mar 23, 2020
P1, N=50, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Recruiting --> Suspended
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date, Trial primary completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Jan 14, 2020
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2020
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date, Trial primary completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Dec 17, 2019
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2020 Trial completion date: Dec 2019 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Jul 2021
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial completion date, Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 4, 2019
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Trial completion date: Dec 2019 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Jul 2021 Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion date, Trial primary completion date: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Oct 2, 2018
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 30, 2018
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Suspended --> Recruiting | Trial completion date: Feb 2022 --> Sep 2020 | Trial primary completion date: Feb 2019 --> Jul 2020
- | Hiltonol (poly-ICLC) / Oncovir
Trial completion: MUC1 Vaccine for Triple-negative Breast Cancer (clinicaltrials.gov) - Jul 23, 2018
P1, N=29, Completed, Sponsor: Joseph Baar, MD, PhD
Suspended --> Recruiting | Trial completion date: Feb 2022 --> Sep 2020 | Trial primary completion date: Feb 2019 --> Jul 2020 Active, not recruiting --> Completed
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment open: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Jan 16, 2018
P1, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
New P1 trial: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - Oct 4, 2017
P1, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial primary completion date, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 28, 2017
P1/2, N=30, Suspended, Sponsor: Olivera Finn
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Feb 2019
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment closed, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Nov 16, 2016
P2, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2017 --> Feb 2019 Recruiting --> Active, not recruiting
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
New P2 trial, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Sep 1, 2016
P2, N=120, Recruiting, Sponsor: Mayo Clinic
- Hiltonol (poly-ICLC) / Oncovir
Enrollment change, Trial primary completion date: MUC1 Vaccine for Triple-negative Breast Cancer (clinicaltrials.gov) - Jun 22, 2015
P0, N=29, Active, not recruiting, Sponsor: Joseph Baar, MD
Recruiting --> Active, not recruiting N=37 --> 29 | Trial primary completion date: Dec 2013 --> Aug 2015
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Trial suspension, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=30, Suspended, Sponsor: Olivera Finn
N=37 --> 29 | Trial primary completion date: Dec 2013 --> Aug 2015 Recruiting --> Suspended
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment open, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Sep 4, 2014
P2, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Suspended --> Recruiting
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial suspension, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Aug 12, 2014
P2, N=120, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial primary completion date, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Jul 2, 2014
P2, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial primary completion date: Mar 2016 --> Jan 2017
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment open, Trial primary completion date, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - Jul 2, 2014
P2, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Jan 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jan 2017
- | Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
New P2 trial, Metastases: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - May 7, 2014
P2, N=120, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Hiltonol (poly-ICLC) / Oncovir
Enrollment closed: MUC1 Vaccine for Triple-negative Breast Cancer (clinicaltrials.gov) - Aug 1, 2013
P0, N=37, Active, not recruiting, Sponsor: Joseph Baar, MD
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Enrollment change, Metastases: Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma (clinicaltrials.gov) - Jan 15, 2013
P2, N=46, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting N=65 --> 46
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh
Trial completion, Metastases: Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma (clinicaltrials.gov) - Jan 15, 2013
P2, N=46, Completed, Sponsor: University of Pittsburgh
N=65 --> 46 Recruiting --> Completed
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
Enrollment open, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 4, 2012
P1/2, N=30, Recruiting, Sponsor: Olivera Finn
Recruiting --> Completed Not yet recruiting --> Recruiting
- Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh, Hiltonol (poly-ICLC) / Oncovir
New P1/2 trial, Metastases: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 31, 2012
P1/2, N=30, Recruiting, Sponsor: Olivera Finn